Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PET3D

Financiado

Cerrado

PET Imaging in Drug Design and Development

The drug development strategy currently pursued by the pharmaceutical industry worldwide is inefficient and unsustainable for the health care system. To keep the latter affordable, drug development should become more efficient and... ver más

31/05/2020

LOUGHBOROUGH UNIVE...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

LOUGHBOROUGH UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-05-31

MSCA-ITN-2015-ETN: Marie Skłodowska-Curie Innovative T...

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

LOUGHBOROUGH UNIVERSITY

165.19K€ | Lider

STICHTING VU

N.D. | Participante

VUB

501.12K€ | Participante

ASTRAZENECA AB

263.66K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PCI2024-153423 Herramientas diagnósticas, pronósticas y terapéuticas 315K€ Cerrado

PTQ-13-05861 Proyecto DynAppHTM. Aplicación de Nuevas Tecnologías Bioanal... 44K€ Cerrado

SAF2014-53977-R HERRAMIENTAS DE RMN PARA EL DESARROLLO DE UNA PLATAFORMA PAR... Cerrado

PCI2024-153519 Herramientas diagnósticas, pronósticas y terapéuticas 135K€ Cerrado

INNOVABALT Strengthening the research and innovation capacities of the... 5M€ Cerrado

RTI2018-096429-B-I00 DESARROLLO DE NUEVAS APROXIMACIONES PARA EL DESCUBRIMIENTO D... 266K€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2016-05-02
Fecha Fin: 2020-05-31

Líder del proyecto

LOUGHBOROUGH UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The drug development strategy currently pursued by the pharmaceutical industry worldwide is inefficient and unsustainable for the health care system. To keep the latter affordable, drug development should become more efficient and drug treatment should become more personalized and rationalized. Molecular imaging can play a pivotal role in changing the landscape of drug design/development and improving the health care system. Positron Emission Tomography (PET) imaging, in particular, is the technology that has the potential to lead this fundamental innovation by providing at a much earlier stage reliable answers to key questions emerging during the care cycle: what and where is the disease? Is the disease accurately targeted by the therapy? Is the treatment effective? By answering the questions above, PET imaging has the capacity to render much more effectively the transition from pre-clinical to clinical phase, and to strongly facilitate the development of better drugs at an earlier stage and in a much more sustainable manner. The main obstacle to this change of paradigm in drug design and development is the lack of suitably trained translational scientists directly involved in PET imaging and imaging scientists with high-profile training in chemistry and PET-radiochemistry, which is particularly dramatic in Europe. This consortium is ideally suited to fill this gap, by providing top-quality training to the next generation of translational PET imaging scientists who will play a key role in shaping the future of drug design and development. The PET3D ETN will focus on 15 cutting-edge research projects in the 3 main therapeutic areas (oncology, cardiovascular, central nervous system) that will be conducted by 15 ESRs at 8 European beneficiary Institutions, 6 academic (all having a PET center on site) and 2 non-academic (one with a PET center on site and one big pharmaceutical company) representing the drug design and development terminus of the project.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores